Cross Country Healthcare Inc
NASDAQ: CCRN · HEALTHCARE · MEDICAL CARE FACILITIES
Updated 2026-04-30
Cross Country Healthcare Inc (CCRN) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for CCRN.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
CCRN historical valuation range
Where current P/E sits in CCRN's own 5Y range.
CCRN intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
CCRN valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 0.31x
Is CCRN overvalued in 2026?
Cross Country Healthcare Inc (CCRN) currently trades at $10.12 per share with a market capitalization of $323,924,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 36/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
CCRN currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 0.3x, the market is valuing the company primarily on its revenue rather than its earnings.
Looking at its own history, CCRN is currently trading cheaper than 100% of the last 5Y on P/E. This places it in the 0th percentile of its historical range, a level that has historically coincided with attractive entry points.
Our discounted cash flow model estimates CCRN's intrinsic value at $35.09 per share, against the current market price of $10.12. This implies a margin of safety of +76.43%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
Financial quality is a concern. The Piotroski F-Score of 2/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: CCRN appears richly valued on our framework, with a Smart Value Score of 36/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is CCRN overvalued in 2026?
Based on a Smart Value Score of 36/100, CCRN appears overvalued. Current price exceeds what fundamentals currently justify.
What is CCRN's fair value?
Our DCF model estimates CCRN's intrinsic value at $35.09 per share, versus the current price of $10.12. This produces a margin of safety of +76.43%.
What P/E ratio does CCRN trade at?
CCRN does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.
Is CCRN a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 36/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does CCRN's valuation compare to its history?
On P/E, CCRN currently sits in the 0th percentile of its own 5Y range. That is historically cheap relative to where it has traded over the period.
What is CCRN's Smart Value Score?
CCRN's Smart Value Score is 36/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.